Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04052698 · ClinicalTrials.gov registry record · Phase 3

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

A Phase 3 study, sponsored by Octapharma.

Completed
Registry status
Phase 3
Development phase
43
Enrollment target

NCT04052698 is a Phase 3 study that has completed, run by Octapharma. The registered enrollment target is 43 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04052698, a Phase 3 study, has completed, sponsored by Octapharma.

COMPLETED
Registry status
Phase 3
Development phase
43 participants
Enrollment target

Study Summary

This is a prospective, non-controlled, international, multi-center phase 3 study investigating the efficacy and safety of Wilate in previously treated adult patients with VWD, to obtain additional data on the safety and efficacy of Wilate in previously treated patients with VWD undergoing regular prophylaxis.

Interventions

  • DRUG Wilate

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2020-06-18
Est. Completion 2022-04-23
Phase Phase 3

Sponsor

Octapharma

43 total trials

What the Registry Record Tells You About NCT04052698

The ClinicalTrials.gov registry entry for NCT04052698 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Wilate is the first listed.

NCT04052698 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04052698 about?

NCT04052698 is a clinical study titled "Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD". This is a prospective, non-controlled, international, multi-center phase 3 study investigating the efficacy and safety of Wilate in previously treated adult patients with VWD, to obtain additional data on the safety and efficacy of Wilate in previously treated patients with VWD undergoing regular pr...

What is the current status of trial NCT04052698?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2020-06-18. Estimated completion is 2022-04-23.

What interventions are being tested in trial NCT04052698?

The interventions under investigation include: Wilate (DRUG).

Who is sponsoring clinical trial NCT04052698?

This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.